For the development of an extremely accurate imaging diagnostic for Alzheimers Disease generic viagra online.

ADDF’s grant to Abiant for developing accurate imaging diagnostic approach The Alzheimer’s Medication Discovery Basis announced today that it is providing a grant of $200,000 to Abiant, Inc. , for the development of an extremely accurate imaging diagnostic for Alzheimer’s Disease. Abiant, a held company privately, is dedicated to the use of neuroimaging to improve the treatment and medical diagnosis of neurologic and neuropsychiatric disorders generic viagra online . Abiant’s diagnostic approach combines key developments in the analysis of Positron Emission Tomography pictures of the mind.

This partnership exemplifies the importance of combining and leveraging available resources to accelerate drug discovery in Alzheimer's. With nearly 44 million people affected by Alzheimer's and related diseases worldwide, and the number increasing, the organizations desire to propel promising drug developments into final phases of assessment and ultimately in the hands of those suffering from these devastating diseases. With current treatments just temporarily helping with symptoms, and not stopping dementia from progressing, new drugs are urgently needed. We are very thrilled to partner with the ADDF and offer this crucial funding to experts on leading lines of dementia study, said Doug Dark brown, PhD, Director of Research and Development at the Alzheimer's Culture.